Skip to Main Content

Buffeted by problems with its all-important diabetes franchise, Sanofi (SNY) is bidding $11.6 billion for Bioverativ (BIVV) — a hemophilia company spun off by Biogen (BIIB) — hoping it will help solve its strategic and financial woes.

But skepticism abounds.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!